Outlook Therapeutics (OTLK) Liabilities and Shareholders Equity (2015 - 2026)

Outlook Therapeutics (OTLK) has reported Liabilities and Shareholders Equity for 12 consecutive years, with $21.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 14.77% year-over-year to $21.9 million; the TTM figure through Mar 2026 stood at $81.1 million (down 27.58% YoY), while the FY2025 annual figure was $18.6 million, down 35.52% from the prior year.
• Liabilities and Shareholders Equity improved to $21.9 million in Q1 2026 per OTLK's latest filing, from $18.2 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $67.7 million in Q1 2022 and bottomed at $17.0 million in Q4 2024.
• Historically, Liabilities and Shareholders Equity has averaged $35.4 million across 5 years, with a median of $28.8 million in 2024.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity jumped 50.04% — and 2025, when it slumped 67.68%.
• Outlook Therapeutics' Liabilities and Shareholders Equity stood at $62.7 million in 2022, then plunged by 65.41% to $21.7 million in 2023, then retreated by 21.58% to $17.0 million in 2024, then advanced by 7.25% to $18.2 million in 2025, then gained by 20.03% to $21.9 million in 2026.
• Business Quant data shows OTLK's Liabilities and Shareholders Equity at $21.9 million in Q1 2026, $18.2 million in Q4 2025, and $18.6 million in Q3 2025.